CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2014—Quest Diagnostics is offering new pathology and blood tests for identifying and assessing an individual’s risk of Lynch syndrome.
The guideline-based test services include a comprehensive blood test panel that evaluates MLH1, MSH2 (and EpCAM terminal deletions), MSH6, and PMS2 for inherited mutations responsible for the majority of Lynch syndrome cases. Gene-specific tests are available for those whose family history or tumor tissue results indicate targeting one or more of these genes. The offering also includes a menu of validated biopsy-tumor screening options for patients with a diagnosis of colorectal, endometrial, or other Lynch-associated cancers.
Quest Diagnostics, 973-520-2800